Trials / Completed
CompletedNCT01176968
Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction
A Double-blind, Randomized, Placebo-controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,012 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Administration of eplerenone within 24 hours of onset of symptoms of myocardial infarction, in patients without heart failure, reduces cardiovascular mortality / morbidity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eplerenone | Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data. |
| DRUG | Placebo | Matching placebo tablets |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2010-08-06
- Last updated
- 2020-12-22
- Results posted
- 2016-08-15
Locations
75 sites across 11 countries: Canada, Czechia, France, Germany, Greece, Hungary, Netherlands, Poland, Slovakia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01176968. Inclusion in this directory is not an endorsement.